" /> Docetaxel/Trastuzumab Regimen - CISMeF





Preferred Label : Docetaxel/Trastuzumab Regimen;

NCIt synonyms : Docetaxel/Trastuzumab; Taxotere/Herceptin; Docetaxel-Trastuzumab Regimen; Docetaxel-Trastuzumab;

NCIt related terms : Docetaxel and Trastuzumab (TH); Docetaxel and Trastuzumab-qyyp (TH); T-H (Docetaxel) (trastuzumab-pkrb); Docetaxel and Trastuzumab-herw (TH); T-H (Docetaxel) (trastuzumab-herw); Docetaxel and Trastuzumab-dttb (TH); T-H (Docetaxel) (trastuzumab-zerc); Docetaxel and Trastuzumab-anns (TH); Docetaxel and Trastuzumab-pkrb (TH); T-H (Docetaxel) (trastuzumab-anns); T-H (Docetaxel) (trastuzumab-dttb); T-H (Docetaxel); T-H (Docetaxel) (trastuzumab-qyyp); T-H (Docetaxel) (trastuzumab-dkst); Docetaxel and Trastuzumab-zerc (TH); Docetaxel and Trastuzumab-dkst (TH); T-H (Docetaxel) (trastuzumab-strf);

NCIt definition : A regimen consisting of docetaxel and trastuzumab that may be used in the treatment of breast, esophageal and esophagogastric junction, and gastric cancers and salivary gland tumors. Docetaxel every 21 days plus trastuzumab regimen may be used for the treatment of breast cancer.;

NCIt note : Source: NCCN Guidelines 2017;

NCI Metathesaurus CUI : CL524997;

Codes from synonyms : 6130; 129028; 136264; 128931; 128834; 136269; 136266; 129222; 136265; 136268; 129125; 136267; 129416; 136271; 136270; 129319; 141431;

Détails


Vous pouvez consulter :


Nous contacter.
29/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.